Combivir (lamivudine plus zidovudine)
Audience: Pharmacists, distributors, and healthcare professionalsGlaxoSmithKline announced that the company received four reports of suspect bottles containing 60 tablets of Combivir (lamivudine plus zidovudine) that actually contained another medicine, Ziagen (abacavir sulfate) Tablets. The company has determined that counterfeit labels for Combivir Tablets were placed on two bottles of Ziagen and labels on another two bottles are suspect. Both medicines are used as part of combination regimens to treat HIV infection. The incidents appear to be isolated and limited in scope. No injuries or adverse reactions have been reported. Company tests have shown no problems with the medicine itself.
[May 14, 2002 Letter to Healthcare Professionals - GlaxoSmithKline] PDF Format
[May 14, 2002 Letter to Pharmacists - GlaxoSmithKline] PDF Format
[May 10, 2002 Press Release - GlaxoSmithKline]
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.